aminocaproic acid

This list is not complete and other drugs may interact with aminocaproic acid.

Stop using aminocaproic acid and call your doctor at once if you have a serious side effect such as:

Treatment with aminocaproic acid is usually continued hourly for 8 hours or until the bleeding has stopped.

Take the aminocaproic acid tablets with a full glass (8 ounces) of water.

Since aminocaproic acid is used as needed, you may not be on a dosing schedule.

Aminocaproic acid may also be used for purposes not listed in this medication guide.

Aminocaproic acid can have long-lasting effects on your body.

Your pharmacist can provide more information about aminocaproic acid.

Aminocaproic acid is either taken by mouth or injected into a vein through an IV.

In water, caprolactam hydrolyzes to aminocaproic acid, which is used medicinally.

Your doctor will perform blood tests to make sure you do not have other conditions that would prevent you from safely using aminocaproic acid.

To make sure you can safely take aminocaproic acid, tell your doctor if you have any of these other conditions:

It is not known whether aminocaproic acid passes into breast milk or if it could harm a nursing baby.

The injectable form of aminocaproic acid must be mixed with a liquid (diluent) before using it.

Two studies published in early 2008, both comparing aprotinin with aminocaproic acid, found that mortality was increased by 32 and 64%, respectively.

Aminocaproic acid is a man-made form of a protein that occurs naturally in the body and helps the blood clot.

Do not use the aminocaproic acid injection if it has changed colors or has particles in it.

Overdose of streptokinase or tPA can be treated with aminocaproic acid.

In tPA overdose, aminocaproic acid works as an antidote.

Before you use aminocaproic acid, tell your doctor if you have kidney disease, or a history of stroke or blood clot.

First-line options include the antifibrinolytics tranexamic acid or aminocaproic acid.

However, the main risk associated with aminocaproic acid is the increased risk for thrombosis because of the inhibition of fibrinolysis.

FDA pregnancy category C. It is not known whether aminocaproic acid will harm an unborn baby.

In contrast, nitric oxide and aminocaproic acid have been shown to worsen EIPH.

Tranexamic acid and aminocaproic acid inhibit fibrinolysis, and lead to a de facto reduced bleeding rate.